Black Diamond Therapeutics, Inc. Common Stock
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Open BDTX dashboard ↗Biohaven Ltd.
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven Ltd. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Open BHVN dashboard ↗